Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2023)

Akebia Therapeutics (AKBA) has disclosed Short term Debt for 4 consecutive years, with $17.5 million as the latest value for Q4 2023.

  • Quarterly Short term Debt fell 45.31% to $17.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Dec 2023, down 45.31% year-over-year, with the annual reading at $17.5 million for FY2023, 45.31% down from the prior year.
  • Short term Debt for Q4 2023 was $17.5 million at Akebia Therapeutics, up from $8.0 million in the prior quarter.
  • The five-year high for Short term Debt was $98.2 million in Q2 2022, with the low at $8.0 million in Q3 2023.
  • Average Short term Debt over 3 years is $51.7 million, with a median of $32.0 million recorded in 2022.
  • Peak annual rise in Short term Debt hit 45.31% in 2023, while the deepest fall reached 87.87% in 2023.
  • Over 3 years, Short term Debt stood at $97.5 million in 2021, then tumbled by 67.19% to $32.0 million in 2022, then plummeted by 45.31% to $17.5 million in 2023.
  • According to Business Quant data, Short term Debt over the past three periods came in at $17.5 million, $8.0 million, and $24.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.